The efficiency of cardiac biomarkers in the identification of patients with acute coronary syndrome


  • Sanaa Gadbaan Almandlawi Department of Internal Clinical Analysis, College of Pharmacy, Hawler Medical University, Erbil, Iraq.
  • Ajheen Muhammad Ali Department of Internal Clinical Analysis, College of Pharmacy, Hawler Medical University, Erbil, Iraq.



Heart-type fatty acid binding protein, Ischemia modified albumin, Myocardial infarction, Troponin I, Unstable angina


Background and objective: This study aimed to differentiate acute myocardial infarction from unstable angina upon the onset of chest pain, by evaluating the usefulness of combined biomarkers troponin I, ischemia modified albumin, and heart-type fatty acid binding protein as early as possible.

Methods: A cross-sectional study was conducted at the Department of Clinical Analysis, College of Pharmacy, Hawler Medical University. This study included 73 patients with suspected acute coronary syndrome, who attended to the Emergency and /or Cardiac Care Unit departments of Hawler Teaching Hospital and Rojhalat Emergency Hospital, Erbil, Iraq, and who were diagnosed with either acute myocardial infarction (n=45) or unstable angina (n=28) between 12 May 2013 and 25 January 2014. Serum troponin I, heart-type fatty acid binding protein, and ischemia modified albumin were determined twice, at between 30 minutes and 4 hours, and between 6 and 12 hours after the onset of chest pain.

Results: For diagnosing and differentiating between acute myocardial infarction and unstable angina, the sensitivity and specificity of serum troponin I cut-off value at (≤4) hours of chest pain was 53.3% and 100%, respectively. The sensitivity and specificity were 97.8% and 96.4 at 6-12 hours after onset of chest pain. The sensitivity and specificity of heart-type fatty acid binding protein cut-off values at (≤4) hours was 48.9% and 100%, respectively, increasing to 84.4% and 100% at 6-12 hours. The combined use of serum troponin I and heart-type fatty acid binding protein enhanced sensitivity to 73.3% at the first interval, and 100% at the second.

Conclusion: A combination of troponin I and heart-type fatty acid binding protein tests improves sensitivity in diagnosing and differentiating acute myocardial infarction and unstable angina within the first 4 hours of chest pain. 


Metrics Loading ...


Anderson JL. ST segment elevation acute myocardial infarction and complication of myocardial infarction. In: Goldman L and Schafer AI, editors, Goldman’s Cecil medicine, 24th ed. Philadelphia: Elsevier Saunders; 2012. P. 434–47.

Nigam PK. Biochemical markers of myocardial injury. Indian J Clin Biochem 2007; 22:10–7.

Christenson RH, Duh SH, Sanhai WR. Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem 2001; 47:464–70.

Anwaruddin S, Januzzi JL, Baggish AL, Lewandrowski EL, Lewandrowski KB. Ischemia-modified albumin improves the usefulness of standard cardiac biomarkers for the diagnosis of myocardial ischemia in the emergency department setting. Am J Clin Pathol 2005; 123:140–5.

Gururajan P, Gurumurthy P, Nayar P, Nageswara GS, Cherian KM. Heart fatty acid binding protein (H-FABP) as a diagnostic biomarker in patients with acute coronary syndrome. Heart Lung Circ 2010; 19:660–4.

Lim W, Holinski P, Devereaux P. Detecting myocardial infarction in critical illness using screening troponin measurements and ECG recordings. Crit Care 2008; 12:36.

Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Eur Heart J 2007; 28:25–38.

Abebe A, Daniels J, Mckean JW, Kapenga JA. Statistics and Data Analysis. Western Michigan University: Kalamazoo MI; 2001. P. 143–85.

Tamimi W, Alothaima A, Alhoda A, Dafterdar R. Evaluation of troponin I in patients with acute myocardial infarction in the emergency department. J Clin Diagn Res 2010; 4:3170–5.

Sangita MP, Banker MP, Padalkar RK, Pathak PA, Bhagat SS, Ghone RA, et al. The Clinical Assessment of Ischaemia Modified Albumin and Troponin I in the Early Diagnosis of the Acute Coronary Syndrome. J Clin Diagn Res 2013; 7:804–8.

Iida K, Nagao K, Uchiyama T, Kushiro T. Relationship between heart-type fatty acid-binding protein levels and the risk of death in patients with serious condition on arrival at the emergency department. Intern Med 2005; 44(10):1039–45.

Chan CP, Sanderson JE, Glatz JF, Cheng WS, Hempel A, Renneberg R. A superior early myocardial infarction marker. Human heart-type fatty acid-binding protein. Z Kardiol 2004; 93:388–97.

Cavus U, Coskun F, Yavuz B, Ciftci O, Sahinere L, Aksoy H, et al. Heart-type, fatty-acid binding protein can be adiagnostic marker in acute coronary syndromes. J Natl Med Assoc 2006; 98:1067–70.

Aktuğlu MB, Tunca O, Atalay E, Acar S, Erez SA, Namık YN, et al. Comparison of heart type free fatty acid binding protein, CPK-MB and troponin-I in the early diagnosis of acute coronary syndrome. Kafkas J Med Sci 2012; 2:109–14.

Reiter M, Twerenbold R, Reichlin T, Mueller M,Hoeller R, Moehring B, et al. Heart-type fatty acid-binding protein in the early diagnosis of acute myocardial infarction. Heart 2013; 99:708–14.

Alansari SE, Croal BL. Diagnostic value of heart fatty acid binding protein and myoglobin in patients admitted with chest pain. Ann Clin Biochem 2004; 41:391–6.

Wudkowska A, Goch J, Goch A. Ischemia−modified albumin in differential diagnosis of acute coronary syndrome without ST elevation and unstable angina pectoris. Kardiol Pol 2010; 68:431–7.




How to Cite

Almandlawi, S. G., & Ali, A. M. (2020). The efficiency of cardiac biomarkers in the identification of patients with acute coronary syndrome. Zanco Journal of Medical Sciences (Zanco J Med Sci), 24(2), 166–175.



Original Articles